Metagenomi Therapeutics (MGX) EPS (Weighted Average and Diluted) (2023 - 2026)
Metagenomi Therapeutics (MGX) reported EPS (Weighted Average and Diluted) of -$0.61 for Q1 2026, up 10.29% year-over-year from -$0.55 in Q1 2025, and down 1.67% quarter-over-quarter from -$0.6 in Q4 2025.
Metagenomi Therapeutics (MGX) EPS (Weighted Average and Diluted) (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has 4 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.61 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.61, up 10.29% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.3 (down 9.0% YoY), and the FY2025 annual result was -$2.36, changed 0.0% from the prior year.
- EPS (Weighted Average and Diluted) retreated to -$0.61 in Q1 2026 per MGX's latest filing, from -$0.6 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at -$0.29 in Q2 2024 and troughed at -$5.82 in Q3 2023.
- A 4-year average of -$1.97 and a median of -$0.63 in 2024 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2024 and 2025: EPS (Weighted Average and Diluted) soared 92.41% in 2024, then plunged 86.21% in 2025.
- A 4-year view of EPS (Weighted Average and Diluted) shows it stood at -$5.67 in 2023, then surged by 88.89% to -$0.63 in 2024, then advanced by 4.76% to -$0.6 in 2025, then dropped by 1.67% to -$0.61 in 2026.
- Business Quant data shows MGX's EPS (Weighted Average and Diluted) at -$0.61 in Q1 2026, -$0.6 in Q4 2025, and -$0.55 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 0.00 |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -0.61 |
| 10 | Metagenomi Therapeutics | 46.60 Mn | 46.60 Mn | - | -0.61 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.61 |
| Dec 31, 2025 | -0.60 |
| Sep 30, 2025 | -0.55 |
| Jun 30, 2025 | -0.54 |
| Mar 31, 2025 | -0.68 |
| Dec 31, 2024 | -0.63 |
| Sep 30, 2024 | -0.51 |
| Jun 30, 2024 | -0.29 |
| Mar 31, 2024 | -1.19 |
| Dec 31, 2023 | -5.67 |
| Sep 30, 2023 | -5.82 |
| Jun 30, 2023 | -3.82 |
| Mar 31, 2023 | -4.74 |